Clinical Effect of Thymosin Combined with Vidarabine on 24 Cases of Chronic Severe Hepatitis B Treatment

Objective To observe the clinical efficacy of thymosin α_(1 )(Tα_(1)) combined with vidarabine on chronic severe hepatitis. Methods Forty-six chronic severe hepatitis B patients were divided into the treatment group (n=24) and the control group (n=22). The control group were treated with vidarabine, and the treatment group with Tα_1 and vidarabine for 8 wk. The serum levels of total bilirubin (T-BiL), alanine aminotransferase (ALT), plasma thromboplastin activity (PTA), endotoxin, interleukin and T-lymphocyte subsets were compared. Results The total effective rate and mortality in treatment group were 71.0%, 29.0%, and in the control group were 41.0%, 59.0%. There was a significant difference between the two groups (P0.05). Conclusion Tα_(1 )combined with vidarabine can lessen the harm of liver function by immune reaction and lower the mortality of chronic severe hepatitis B.